• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Walz, C
    Erben, P
    Ritter, M
    Bloor, Adrian
    Metzgeroth, G
    Telford, Nicholas
    Haferlach, C
    Haferlach, T
    Gesk, S
    Score, J
    Hofmann, W-K
    Hochhaus, A
    Cross, N C P
    Reiter, A
    Show allShow less
    Affiliation
    Pathologisches Institut, Ludwig-Maximilians-Universität, München, Germany.
    Issue Date
    2011-08-25
    
    Metadata
    Show full item record
    Abstract
    Imatinib-resistant tyrosine kinase (TK) fusions involving FGFR1, JAK2, or FLT3 are rare but recurrent in patients with eosinophilia-associated neoplasms. We report here 2 male patients with ETV6-FLT3(+) myeloid/lymphoid neoplasms with eosinophilia who were treated with the multitargeted TK inhibitors sunitinib and sorafenib. Patient 1 achieved rapid complete hematologic response and complete cytogenetic response after 3 months of taking sunitinib. A secondary blast phase caused by clonal evolution was diagnosed after 6 months. He achieved a second complete hematologic response after taking sorafenib but relapsed 2 months later. An N841K point mutation within the TK domain of FLT3, previously reported in acute myeloid leukemia and potentially conferring resistance to sorafenib, was subsequently identified. Patient 2 was heavily pretreated according to the initial diagnosis of T-lymphoblastic lymphoma and died in sunitinib-induced pancytopenia. This report highlights the importance of a careful diagnostic workup for eosinophilia-associated neoplasms to evaluate the possibility of TK inhibitor therapy.
    Citation
    Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. 2011, 118 (8):2239-42 Blood
    Journal
    Blood
    URI
    http://hdl.handle.net/10541/229166
    DOI
    10.1182/blood-2011-03-343426
    PubMed ID
    21705501
    Type
    Article
    Language
    en
    ISSN
    1528-0020
    ae974a485f413a2113503eed53cd6c53
    10.1182/blood-2011-03-343426
    Scopus Count
    Collections
    All Christie Publications
    Pathology
    Haematology

    entitlement

    Related articles

    • Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement.
    • Authors: Shao H, Wang W, Song J, Tang G, Zhang X, Tang Z, Srivastava J, Shah B, Medeiros LJ, Zhang L
    • Issue date: 2020 Dec
    • Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
    • Authors: Kancha RK, Grundler R, Peschel C, Duyster J
    • Issue date: 2007 Oct
    • Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.
    • Authors: Baker SD, Zimmerman EI, Wang YD, Orwick S, Zatechka DS, Buaboonnam J, Neale GA, Olsen SR, Enemark EJ, Shurtleff S, Rubnitz JE, Mullighan CG, Inaba H
    • Issue date: 2013 Oct 15
    • T cell phenotype and lack of eosinophilia are not uncommon in extramedullary myeloid/lymphoid neoplasms with ETV6::FLT3 fusion: a case report and review of the literature.
    • Authors: Schoelinck J, Gervasoni J, Guillermin Y, Beillard E, Pissaloux D, Chassagne-Clement C
    • Issue date: 2024 May
    • Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib.
    • Authors: von Bubnoff N, Rummelt C, Menzel H, Sigl M, Peschel C, Duyster J
    • Issue date: 2010 Aug
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.